Andersson KE

제1저자 또는 공저자로 매칭된 논문 · word-boundary on `authors` column

4 논문
2015–2018 활동기

주요 저널

  • Neurourology and urodynamics 1
  • Minerva urologica e nefrologica = The Italian journal of urology and nephrology 1
  • Korean journal of urology 1
  • Basic & clinical pharmacology & toxicology 1

주요 공저자 Top 8

  1. Fry CH 1편
  2. Kitney DG 1편
  3. Paniker J 1편
  4. Drake MJ 1편
  5. Kanai A 1편
  6. Lombardo R 1편
  7. Tubaro A 1편
  8. De Nunzio C 1편

연도별 분포

  • 2018 2
  • 2016 1
  • 2015 1

최근 발표

공저자 네트워크

중심 = Andersson KE · 공저 횟수 상위 30
공저자 엣지
본인 공저자 본인-공저자 공저자 사이
⏳ 그래프 로딩 중…

노드 더블클릭 = 해당 저자 페이지로 이동 · 호버 = 공저 횟수 툴팁

논문 목록

4건 · 최신순
  • Fibrosis and the bladder, implications for function ICI-RS 2017.
    Neurourology and urodynamics 2018 Fry CH 외 PMID: 30133788

    [AIMS] Most benign bladder pathologies are associated with an increase of extracellular matrix (ECM-fibrosis) and may progress from formation of stiffer matrix to a more compliant structure. The aims were to summarize current knowledge of t…

  • Intraprostatic injections for lower urinary tract symptoms/benign prostatic enlargement treatment.
    Minerva urologica e nefrologica = The Italian journal of urology and nephrology 2018 Lombardo R 외 PMID: 30298711

    [INTRODUCTION] Endoscopic surgical treatment represents the gold standard in patients with lower urinary tract symptoms (LUTS) when medical treatment fails. In the past years there has been a growing interest in intraprostatic injections wh…

  • Potential Future Pharmacological Treatment of Bladder Dysfunction.
    Basic & clinical pharmacology & toxicology 2016 Andersson KE (제1저자) PMID: 26990140

    In the last decades, a number of new antimuscarinic drugs have been introduced for treatment of the overactive bladder (OAB), defined symptomatically (OAB syndrome) or urodynamically (detrusor overactivity). Recently, three new drug princip…

  • Drug therapy of overactive bladder--what is coming next?
    Korean journal of urology 2015 Andersson KE (제1저자) PMID: 26495067

    After the approval and introduction of mirabegron, tadalafil, and botulinum toxin A for treatment of lower urinary tract symptoms/overactive bladder, focus of interest has been on their place in therapy versus the previous gold standard, an…